Kindstar Globalgene Technology, Inc. (HKG:9960)
Hong Kong · Delayed Price · Currency is HKD 0.9200
-0.0250 (-2.65%)
Sep 11, 2026, 4:08 PM HKT
HKG:9960 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 950.26 | 933.57 | 927.57 | 967.26 | 1,387 | 930.67 |
Revenue Growth | 1.79% | 0.65% | -4.10% | -30.24% | 48.99% | 4.41% |
Gross Profit Gross Profit Growth | 432.87 | 411.38 | 442.94 | 452.21 | 607.28 | 487.92 |
Operating Income Operating Income Growth | -148.42 | -174.69 | -164.04 | -83.99 | 27.19 | 28.13 |
Net Income Net Income Growth | -41.53 | -58.74 | -54.59 | 41.29 | 75.46 | -1,454 |
Earnings Per Share EPS Growth | -0.04 | -0.06 | -0.06 | 0.04 | 0.09 | -2.93 |
EPS Growth | - | - | - | -53.90% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Neurology Testing Neurology Testing Growth | 94.42 | 95.05 | 95.35 | 96.6 | 95.35 | 89.85 |
Genetic Disease and Rare Diseases Genetic Disease and Rare Diseases Growth | 39.63 | 40.94 | 44.75 | 46.72 | 42.78 | 43.5 |
Routine Testing Routine Testing Growth | 40.77 | 41.28 | 42.39 | 57.47 | 57.44 | 67.67 |
Hematology Testing Hematology Testing Growth | 568.08 | 563.13 | 585.11 | 590.31 | 525.8 | 535.27 |
Scientific research services and CRO Scientific research services and CRO Growth | 58.33 | 59.57 | 44.66 | 26.39 | 7.94 | - |
Others Others Growth | 10.57 | 3.12 | 0.28 | 13.29 | 5.14 | 19.46 |
Oncology Testing Oncology Testing Growth | 58.43 | 44.8 | 21.72 | 32.06 | 17.87 | 8.62 |
Maternity-Related Testing Maternity-Related Testing Growth | 49.95 | 50.24 | 53.88 | 55.42 | 49.96 | 52.25 |
Infectious Diseases Infectious Diseases Growth | 30.09 | 35.44 | 39.43 | 49 | 47.69 | 51.97 |
Total Total Growth | 950.26 | 933.57 | 927.57 | 967.26 | 1,387 | 930.67 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,799 | 1,603 | 1,656 | 2,058 | 2,033 | 2,165 |
Total Debt Total Debt Growth | 394.97 | 413.85 | 398.36 | 194.29 | 199.86 | 18.19 |
Net Cash (Debt) Net Cash Growth | 1,404 | 1,189 | 1,257 | 1,864 | 1,833 | 2,147 |
Net Cash Growth | 18.08% | -5.44% | -32.54% | 1.70% | -14.61% | - |
Net Cash Per Share Net Cash Per Share Growth | 1.38 | 1.20 | 1.33 | 1.92 | 2.24 | 4.33 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 165.02 | 91.17 | -44.12 | -14.78 | 21.41 | 68.03 |
Capital Expenditures CapEx Growth | -43.84 | -45.77 | -132.32 | -168.76 | -119.67 | -281.65 |
Free Cash Flow Free Cash Flow Growth | 121.18 | 45.4 | -176.44 | -183.54 | -98.26 | -213.62 |
Free Cash Flow Growth | 166.91% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 45.55% | 44.07% | 47.75% | 46.75% | 43.80% | 52.43% |
Operating Margin | -15.62% | -18.71% | -17.69% | -8.68% | 1.96% | 3.02% |
Pretax Margin | -2.59% | -4.33% | -6.06% | 4.48% | 6.01% | -156.23% |
Profit Margin | -4.37% | -6.29% | -5.88% | 4.27% | 5.44% | -156.28% |
FCF Margin | 12.75% | 4.86% | -19.02% | -18.98% | -7.09% | -22.95% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.095 | 0.085 | 0.022 | 0.026 |
Dividend Per Share Growth | 299.16% | 281.71% | -13.24% | - |
Dividend Yield | 9.50% | 9.33% | 2.26% | 1.93% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 35.41 | 32.80 | - |
Forward PE | - | 9.11 | 8.37 | 14.52 | 26.63 | 37.35 |
P/FCF Ratio | 6.72 | 22.09 | - | - | - | - |
PS Ratio | 0.86 | 1.07 | 1.17 | 1.51 | 1.79 | 4.52 |